Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients

Five to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy. Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high. This study shows the striking effect of combined dapsone and col...

Descripción completa

Detalles Bibliográficos
Autores principales: Salehzadeh, Farhad, Enteshary, A., Moshkbar, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343160/
https://www.ncbi.nlm.nih.gov/pubmed/30729059
http://dx.doi.org/10.1155/2019/2716127
_version_ 1783389232627187712
author Salehzadeh, Farhad
Enteshary, A.
Moshkbar, M.
author_facet Salehzadeh, Farhad
Enteshary, A.
Moshkbar, M.
author_sort Salehzadeh, Farhad
collection PubMed
description Five to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy. Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high. This study shows the striking effect of combined dapsone and colchicine therapy in such patients and recommends it as an alternative therapy in colchicine-resistant (CR) patients.
format Online
Article
Text
id pubmed-6343160
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-63431602019-02-06 Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients Salehzadeh, Farhad Enteshary, A. Moshkbar, M. Case Rep Rheumatol Case Report Five to ten percent of FMF patients have unfavorable response to the colchicine as a standard therapy. Biologic treatments have been shown to be highly effective, but there are often unavailable, because the price is unaffordably high. This study shows the striking effect of combined dapsone and colchicine therapy in such patients and recommends it as an alternative therapy in colchicine-resistant (CR) patients. Hindawi 2019-01-09 /pmc/articles/PMC6343160/ /pubmed/30729059 http://dx.doi.org/10.1155/2019/2716127 Text en Copyright © 2019 Farhad Salehzadeh et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Salehzadeh, Farhad
Enteshary, A.
Moshkbar, M.
Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
title Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
title_full Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
title_fullStr Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
title_full_unstemmed Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
title_short Colchicine plus Dapsone in Colchicine‐Resistant FMF Patients
title_sort colchicine plus dapsone in colchicine‐resistant fmf patients
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343160/
https://www.ncbi.nlm.nih.gov/pubmed/30729059
http://dx.doi.org/10.1155/2019/2716127
work_keys_str_mv AT salehzadehfarhad colchicineplusdapsoneincolchicineresistantfmfpatients
AT entesharya colchicineplusdapsoneincolchicineresistantfmfpatients
AT moshkbarm colchicineplusdapsoneincolchicineresistantfmfpatients

Ejemplares similares